Founded to focus on novel

Aluda was founded around the idea that we need new approaches to drug discovery to find fundamentally new categories and identify better, more powerful intervention points against disease. We bring a deep, networked view of existing drug MOAs and screening approaches for of the past 30 years, from pathways to genetics, as well as a knowledge of fundamental cell biology. Our focus is on novel targets that have been unseen and under-recognized versus their impact on the complex nature of disease.

Disease is always complex — it is never one cause, one event — and the relationship between its many features is not always linear or related. Existing precision and targeted strategies have not made enough progress against the toughest challenge — when and how it progresses to multi-factor, multi-feature forms that evade and escape existing treatments. We seek to find a new generation of targets with more holistic roles that regulate and control changes in cellular processes from healthy to harmful.

New targets that capture the complexity of disease

Our targets often have complex and subtle biology, rejected by standard thinking and lacking characteristics that make them legible to AI. This can include targets where the challenge is not the target per se but correctly understanding a change in that target biology that can become an intervention point to stop disease.

We believe phenotypic screening designed to identify more holistic disease biology will produce a new generation of drugs with more complete action able to succeed against complex disease.

Drug discovery, rebuilt to discover novel

We design new drug molecules with attractive properties and clear patentability. We do not look for new uses for old drugs (repurposing). We incorporate all state-of-the-art drug discovery tools including CRISPR, proteomic array analysis, big data, and across genetics and molecular medicine, fundamental cell biology, big data, and chemical design, and we pioneered new proprietary concepts in phenotypic screening. Our innovative pharmacological approaches have often exposed gaps in gold standard models by illuminating a disease driving biology not reiterated in the model.

Indication selection clinical strategy

Our focus on the severe sector within immune and fibrotic diseases allows us to create clinical strategies with approval paths around differentiating features not present in other drugs. Severe and complex patients are often excluded from trials. They are our central focus.

This generally avoids head-to-head studies. It shortens timelines to patients, enrolls for these specific features in their severe disease condition, and provides clear differentiation for pricing rationale.